AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 32 min read$JSPR

Jasper Therapeutics, Inc. (JSPR): Submission of Matters to a Vote of Security Holders

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001788028 0001788028 2026-07-31 2026-07-31 0001788028 JSPR:VotingCommonStockParValue0.0001PerShareMember 2026-07-31 2026-07-31 0001788028 JSPR:RedeemableWarrantsEachTenWarrantsExercisableForOneShareOfVotingCommonStockAtExercisePriceOf115.00Member 2026-07-31 2026-07-31 iso4

Original reporting
SEC EDGAR 8-K
Published Aug 3, 2026, 8:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$JSPR
Neutral
high confidence
Mentioned
$JSPR
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$JSPRNeutralLow
01

Why it matters

The disclosure confirms corporate governance actions (two Class II director elections, ratification of PwC as auditor, and advisory approval of executive compensation). It does not provide new financial metrics, guidance, or material corporate transactions.

02

Market read

Primarily administrative governance reporting; not a catalyst for fundamental repricing.

03

What to watch

Traders should check the full 8-K for any additional items beyond Item 5.07; this excerpt appears limited to voting results.

Relevance 6/10Novelty 2/10Timing: filed after market close on Aug 3, 2026

Background

The company’s 8-K (Item 5.07) reports the results of proposals voted on at its 2026 annual meeting held July 31, 2026.

Company-level read

Ticker impact

$JSPRNeutralHigh confidence
Context

Jasper Therapeutics filed an 8-K reporting voting results from its July 31, 2026 annual meeting, including director elections and auditor ratification.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around governance outcomes.

Evidence & confidence

The filing only summarizes shareholder votes (board nominees, auditor ratification, advisory say-on-pay) and does not introduce new business, clinical, regulatory, or capital-structure terms.

Market effects

Sector

Minimal; governance vote outcomes do not typically change biotech sector risk premia.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

If vote outcomes were unusually close or contentious, it could hint at shareholder dissatisfaction, but the excerpt provides no such context.

Key entities

  • issuer
    Jasper Therapeutics, Inc.

    Subject of the SEC 8-K reporting annual meeting voting results.

  • auditor
    PricewaterhouseCoopers LLP

    Ratified by shareholders as independent registered public accounting firm for fiscal year ending Dec 31, 2026.

Read at source← All news

Related articles

AUG 17
$JSPRMed

Jasper Therapeutics beats Q2 expectations but shares fall after results

Jasper Therapeutics (NASDAQ:JSPR) reported Q2 2026 adjusted loss of $0.10 per share, better than the $0.28 consensus, and a net loss of $2.8 million. Shares fell 4.24% pre-market. In July, Jasper completed an all-stock acquisition of Kira Pharmaceuticals and a $132 million private placement, extending its funding runway into 2H 2028. Pipeline updates include KP-104 Phase 2 interim data in Q4 2026 and briquilimab and KP-701 milestones in early 2027.

yahoo.com4 min
AUG 14
$JSPRMed

Jasper Therapeutics, Inc. (JSPR): Results of Operations and Financial Condition

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030204901ex99-1.htm PRESS RELEASE, DATED AUGUST 14, 2026 Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio

SEC EDGAR 8-K6 min
AUG 14
$JSPRMedAI 8/10

Jasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline

Jasper Therapeutics (JSPR) reported Q2 2026 results and a corporate update after completing its all-stock acquisition of Kira Pharmaceuticals on July 16, 2026. The company raised about $132M via a private placement of non-voting convertible preferred stock. Cash was $7.3M at June 30. Net loss was $2.8M. Pipeline updates include KP-104, briquilimab, and KP-701.

rttnews.com6 min
JUL 20
$JSPRMedAI 9/10

Jasper Therapeutics merges with Kira Pharmaceuticals

Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, forming a combined Nasdaq-listed company under ticker JSPR. The deal includes a $132M private placement and a $12M Mirador out-licensing payment on signing, funding operations through H2 2028. Pipeline includes KP-104, briquilimab, and KP-701 with upcoming clinical milestones.

pharmatimes.com5 min
JUL 17
$JSPRMed

Jasper Therapeutics, Inc. (JSPR): Completion of Acquisition or Disposition of Assets

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ea029822901ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED JULY 16, 2026, BY AND AMONG JASPER THERAPEUTICS, INC., KIRA HOLDCO INC. AND KIRA PHARMACEUTICALS Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: JASPER THERAPEUTICS, INC., a Delaware corporation; KIRA HOLDCO INC.,

SEC EDGAR 8-K6 min